{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:14Z","timestamp":1793459654287,"version":"4.5.0"},"reference-count":21,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2020,7,22]]},"DOI":"10.1253\/circj.cj-20-0084","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T18:05:29Z","timestamp":1593799529000},"page":"1330-1338","source":"Crossref","is-referenced-by-count":15,"title":["Direct Oral Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism in Routine Clinical Practice"],"prefix":"10.1253","volume":"84","author":[{"given":"Yutaka","family":"Ogino","sequence":"first","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ishigami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Minamimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Maejima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Iwahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hibi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kosuge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ebina","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. <i>J Clin Oncol<\/i> 2009; 27: 4839\u20134847.","DOI":"10.1200\/JCO.2009.22.3271"},{"key":"2","unstructured":"2. JCS Joint Working Group. Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2017_ito_h.pdf (accessed December 10, 2018)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematol<\/i> 2016; 3: e379\u2013e387.","DOI":"10.1016\/S2352-3026(16)30057-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematol<\/i> 2014; 1: e37\u2013e46.","DOI":"10.1016\/S2352-3026(14)70018-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: Results from the AMPLIFY trial. <i>J Thromb Haemost<\/i> 2015; 13: 2187\u20132191.","DOI":"10.1111\/jth.13153"},{"key":"6","unstructured":"6. Ohgi S, Kanaoka Y. Ultrasound diagnosis of deep vein thrombosis as embolic sources. <i>Jpn J Med Ultrasonics<\/i> 2004; 31: 337\u2013346."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>J Thromb Haemost<\/i> 2005; 3: 692\u2013694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Anticoagulation therapy for venous thromboembolism in the real world: From the COMMAND VTE Registry. <i>Circ J<\/i> 2018; 82: 1262\u20131270.","DOI":"10.1253\/circj.CJ-17-1128"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. <i>Chest<\/i> 2010; 138: 1093\u20131100.","DOI":"10.1378\/chest.10-0134"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). <i>J Clin Oncol<\/i> 2018; 36: 2017\u20132023.","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE Cancer study. <i>Thromb Haemost<\/i> 2018; 118: 1439\u20131449.","DOI":"10.1055\/s-0038-1667001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. <i>Arch Intern Med<\/i> 2006; 166: 853\u2013859.","DOI":"10.1001\/archinte.166.8.853"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D\u2019Angelo A, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. <i>Lancet<\/i> 1996; 348: 423\u2013428.","DOI":"10.1016\/S0140-6736(96)01109-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). <i>Am Heart J<\/i> 2006; 151: 713\u2013719.","DOI":"10.1016\/j.ahj.2005.04.017"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. <i>Clin Pharmacokinet<\/i> 2013; 52: 243\u2013254.","DOI":"10.1007\/s40262-013-0034-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. <i>J Clin Pharmacol<\/i> 2015; 55: 1395\u20131405.","DOI":"10.1002\/jcph.550"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sakamoto J, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, et al; COMMAND VTE Registry Investigators. Cancer-associated venous thromboembolism in the real world: From the COMMAND VTE Registry. <i>Circ J<\/i> 2019; 83: 2271\u20132281.","DOI":"10.1253\/circj.CJ-19-0515"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nakamura M, Miyata T, Ozeki Y, Takayama M, Komori K, Yamada N, et al. Current venous thromboembolism management and outcomes in Japan. <i>Circ J<\/i> 2014; 78: 708\u2013717.","DOI":"10.1253\/circj.CJ-13-0886"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. <i>Thromb Haemost<\/i> 2002; 88: 407\u2013414.","DOI":"10.1055\/s-0037-1613230"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. <i>Blood<\/i> 2002; 100: 3484\u20133488.","DOI":"10.1182\/blood-2002-01-0108"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yamashita Y, Shiomi H, Morimoto T, Yoneda T, Yamada C, Makiyama T, et al. Asymptomatic lower extremity deep vein thrombosis: Clinical characteristics, management strategies, and long-term outcomes. <i>Circ J<\/i> 2017; 81: 1936\u20131944.","DOI":"10.1253\/circj.CJ-17-0445"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/8\/84_CJ-20-0084\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:20:18Z","timestamp":1595632818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/8\/84_CJ-20-0084\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-20-0084","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}